LIFECORE BIOMEDICAL, INC. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
LIFECORE BIOMEDICAL, INC. (LFCR) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $31.10 million for the 12-month period ending 2012-05-27, per its 10-K filed 2012-08-08.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2013-01-02
- LIFECORE BIOMEDICAL, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2012-05-27 was $21.98M.
- LIFECORE BIOMEDICAL, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2011-08-28 was $14.18M.
- LIFECORE BIOMEDICAL, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2011-05-29 was -$1.44M.
- LIFECORE BIOMEDICAL, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2012 was $31.10M, a 25.20% increase from fiscal 2011.
- LIFECORE BIOMEDICAL, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2011 was $24.84M, a 58.57% decline from fiscal 2010.
- LIFECORE BIOMEDICAL, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2010 was $59.97M.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2012-05-27 | $21.98M derived: 10-K 12 month − 10-Q 9 month · filed 2012-08-08 | $31.10M 10-K · filed 2012-08-08 | ||
| 2012-02-26 | $9.13M 10-Q · filed 2012-03-28 | |||
| 2011-08-28 | $14.18M 10-Q/A · filed 2013-01-02 | $12.73M derived: sum of 2 quarters · filed 2013-01-02 | ||
| 2011-05-29 | -$1.44M derived: 10-K 12 month − 10-Q 9 month · filed 2012-08-08 | $24.84M 10-K · filed 2012-08-08 | ||
| 2011-02-27 | $26.29M 10-Q · filed 2012-03-28 | |||
| 2010-05-30 | $59.97M 10-K · filed 2012-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |